By admin 
CureSearch for Children’s Cancer, a national non-profit organization dedicated to ending childhood cancer by driving targeted and innovative research, has officially announced the appointment of Osama Alsaleh to its Board of Directors. The addition of Alsaleh, a prominent figure in healthcare technology and venture capital, marks a strategic move by the organization to bridge the gap between laboratory research and commercialized medical solutions. As the Head of Partnerships at Plug and Play Health—the healthcare arm of one of the world’s most active venture capital firms and global innovation platforms—Alsaleh brings a wealth of experience in scaling health-tech startups and fostering multi-sector collaborations.
The appointment comes at a critical juncture for pediatric oncology, a field that has historically faced significant hurdles in attracting private investment compared to adult oncology. By integrating Alsaleh’s expertise in strategic partnerships and innovation ecosystems, CureSearch aims to accelerate the development of new therapies, ensuring that life-saving discoveries move through the clinical pipeline with greater efficiency.
A Career Defined by Innovation and Health Equity
Osama Alsaleh’s professional trajectory reflects a deep-seated commitment to transforming healthcare through technology and strategic investment. Prior to his current leadership role at Plug and Play Health, Alsaleh held several pivotal positions at Oracle Health (formerly Cerner), where he was instrumental in shaping the company’s approach to global health and social impact.
One of his most notable achievements was the conceptualization and leadership of Oracle’s health equity team. In this capacity, he designed strategies to address social determinants of health (SDOH), ensuring that technological advancements in healthcare were accessible to underserved populations. This focus on equity is particularly relevant to pediatric cancer, where access to specialized care and cutting-edge clinical trials can vary significantly based on a family’s socioeconomic status or geographic location.
Furthermore, Alsaleh’s experience with the Oracle Charitable Foundation Clinical Decision Committee provided him with a unique perspective on the intersection of philanthropy and clinical efficacy. During his tenure, he contributed to the evaluation and distribution of more than $42 million in healthcare grants. This experience in high-stakes philanthropic decision-making aligns perfectly with CureSearch’s mission to fund only the most promising research with the highest potential for clinical impact.
Bridging the Gap: The Challenges of Pediatric Oncology Funding
To understand the significance of Alsaleh’s appointment, it is necessary to examine the current landscape of pediatric cancer research and funding. Despite cancer being the leading cause of death by disease for children in the United States, pediatric oncology receives a disproportionately small amount of federal and private research funding.
According to data from the National Cancer Institute (NCI), only about 4% of the federal budget for cancer research is specifically allocated to childhood cancers. While philanthropic organizations like CureSearch work tirelessly to fill this void, the "Valley of Death"—the gap between initial laboratory discovery and the start of clinical trials—remains a formidable barrier. For many pharmaceutical companies, the relatively small patient population in pediatrics offers less incentive for the high-cost, high-risk development of new drugs compared to adult cancers like lung or breast cancer.
By bringing a venture capital expert like Alsaleh onto its board, CureSearch is positioning itself to navigate these economic realities. His ability to connect startups, healthcare institutions, and corporate partners can help create new "venture philanthropy" models, where donor dollars are used to de-risk early-stage research, making it more attractive for private investment and eventual commercialization.
Chronology of Strategic Leadership and Public Service
Alsaleh’s career is characterized by a blend of private sector success and public sector advocacy. His involvement in high-level regulatory and governmental initiatives has provided him with a comprehensive understanding of the healthcare ecosystem:
- Early Career and Global Initiatives: Alsaleh’s foundational work spanned international organizations including the World Bank Group and the World Health Organization (WHO), where he focused on sustainable global health solutions.
- Oracle and Cerner Leadership: During his tenure at Oracle Health, he moved from technical and strategic roles to leadership in health equity and philanthropic grant allocation.
- National Taskforce Contributions: He served as a strategic advisor on quality reporting measures and collaborated with the White House COVID-19 Taskforce and the U.S. State Department during the height of the global pandemic.
- Plug and Play Health: In his current role, he oversees partnerships that connect the world’s largest corporations with disruptive startups in the digital health and biotech sectors.
This timeline illustrates a consistent focus on convening disparate leaders—from government officials to tech entrepreneurs—to solve complex healthcare challenges.
Official Responses and Organizational Vision
The leadership at CureSearch has expressed high expectations for the impact Alsaleh will have on the organization’s strategic direction. Jared Brancazio, Chair of the CureSearch Board of Directors, emphasized the importance of Alsaleh’s unique professional lens.
"Osama brings a unique and highly valuable perspective to CureSearch," Brancazio stated. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
In his own statement, Alsaleh highlighted the systemic underrepresentation of pediatric needs in the broader innovation landscape. "Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh said. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer."
Broader Implications for the Pediatric Research Landscape
The appointment of a venture capital leader to a non-profit board signifies a growing trend in the charitable sector: the move toward "impact-driven" philanthropy. In this model, the goal is not just to fund research, but to manage that research as a portfolio of assets that must reach the "market" (the patient) to be successful.
For CureSearch, Alsaleh’s expertise will likely influence several key areas:
- Technology Integration: His background in Healthcare IT and AI could assist CureSearch in identifying research projects that utilize big data and machine learning to identify new drug targets more quickly.
- Strategic Partnerships: With connections at Plug and Play, Alsaleh can introduce CureSearch-funded researchers to biotech accelerators that provide the infrastructure needed to turn a discovery into a viable startup.
- Regulatory Navigation: His experience with CMS (Centers for Medicare & Medicaid Services) and the U.S. State Department will be invaluable as CureSearch navigates the complex regulatory pathways required for pediatric drug approval, including the implementation of the RACE for Children Act.
Data-Driven Need for New Therapies
The urgency of CureSearch’s mission is underscored by sobering statistics. While the overall five-year survival rate for childhood cancer has increased to over 80% since the 1970s, this number is misleading for many specific types of cancer. For instance, the survival rate for certain high-risk neuroblastomas or brain tumors like Diffuse Intrinsic Pontine Glioma (DIPG) remains devastatingly low, often near 0%.
Furthermore, many survivors of childhood cancer suffer from "late effects" of the toxic treatments they received as children. By the age of 50, more than 99% of childhood cancer survivors have a chronic health problem, and 96% have a severe or life-threatening condition caused by the very chemotherapy and radiation that saved their lives. The expertise Alsaleh brings to the table is expected to help CureSearch pivot toward "smarter," less toxic therapies that offer not just survival, but a high quality of life.
Conclusion
As CureSearch for Children’s Cancer welcomes Osama Alsaleh, the organization reaffirms its commitment to a future where every child diagnosed with cancer can be guaranteed a cure. By merging the compassionate mission of a non-profit with the strategic rigor of venture capital and global technology leadership, CureSearch is setting a new standard for how pediatric research is funded and developed. The integration of Alsaleh’s global network and innovation-centric mindset is a promising step forward in the collective effort to outpace cancer and provide hope to thousands of families worldwide.
